ATE267213T1 - Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind - Google Patents
Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sindInfo
- Publication number
- ATE267213T1 ATE267213T1 AT98948429T AT98948429T ATE267213T1 AT E267213 T1 ATE267213 T1 AT E267213T1 AT 98948429 T AT98948429 T AT 98948429T AT 98948429 T AT98948429 T AT 98948429T AT E267213 T1 ATE267213 T1 AT E267213T1
- Authority
- AT
- Austria
- Prior art keywords
- cea
- agonists
- antagonists
- peptides
- antigen
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 abstract 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 abstract 4
- 102100027241 Adenylyl cyclase-associated protein 1 Human genes 0.000 abstract 1
- 108010077333 CAP1-6D Proteins 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 108010031970 prostasin Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pregnancy & Childbirth (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6158997P | 1997-10-10 | 1997-10-10 | |
PCT/US1998/019794 WO1999019478A1 (en) | 1997-10-10 | 1998-09-22 | Agonist and antagonist peptides of carcinoembryonic antigen (cea) |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE267213T1 true ATE267213T1 (de) | 2004-06-15 |
Family
ID=22036775
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04011673T ATE364048T1 (de) | 1997-10-10 | 1998-09-22 | Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität |
AT98948429T ATE267213T1 (de) | 1997-10-10 | 1998-09-22 | Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04011673T ATE364048T1 (de) | 1997-10-10 | 1998-09-22 | Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1017810B1 (de) |
JP (1) | JP4291508B2 (de) |
AT (2) | ATE364048T1 (de) |
AU (1) | AU745863B2 (de) |
CA (1) | CA2308127C (de) |
CY (1) | CY1107706T1 (de) |
DE (2) | DE69837896T2 (de) |
DK (1) | DK1447414T3 (de) |
ES (2) | ES2217585T3 (de) |
PT (1) | PT1447414E (de) |
WO (1) | WO1999019478A1 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9923309D0 (en) * | 1999-10-01 | 1999-12-08 | Glaxo Group Ltd | Assay |
ES2447115T3 (es) * | 1999-10-11 | 2014-03-11 | Institut Pasteur | Vectores para la preparación de composiciones inmunoterapéuticas |
DK1227837T3 (da) | 1999-10-22 | 2008-09-15 | Aventis Pasteur | Fremgangsmåde til introduktion og/eller fremskyndelse af et immunrespons på et tumorantigen |
CA2416893A1 (en) * | 2000-07-31 | 2002-02-07 | Aventis Pasteur Limited | Modified cea and uses thereof |
AU2003203140A1 (en) * | 2002-01-17 | 2003-07-30 | Pharmexa A/S | Immunogenic carcinoembryonic antigen (cea) |
US6949629B2 (en) | 2002-03-13 | 2005-09-27 | Aspenbio, Inc. | Methods for purifying selected CEA family member proteins |
EP2301356A3 (de) * | 2002-12-04 | 2012-05-30 | Baylor Research Institute | Schnelles Ein-Schritt-Verfahren zur Erzeugung eines Antigen-geladenen dendritischen Impfstoffs aus Vorläufern |
CN102370974B (zh) * | 2002-12-16 | 2014-09-17 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
US7457855B2 (en) | 2004-04-30 | 2008-11-25 | Aol Llc | Network configuration management |
EP3061462B1 (de) | 2007-07-02 | 2019-02-27 | Etubics Corporation | Verfahren und zusammensetzungen zur erzeugung eines adenovirusvektors zur verwendung mit mehreren impfungen |
WO2009015841A1 (en) | 2007-07-27 | 2009-02-05 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
JP5792630B2 (ja) | 2009-01-28 | 2015-10-14 | エピミューン,インコーポレイティド | Pan−dr結合ポリペプチドおよびその使用 |
ES2660597T3 (es) | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
KR102193635B1 (ko) | 2015-01-09 | 2020-12-21 | 이투빅스 코포레이션 | 복합 면역요법을 위한 방법 및 조성물 |
WO2016112188A1 (en) | 2015-01-09 | 2016-07-14 | Etubics Corporation | Methods and compositions for ebola virus vaccination |
WO2016172249A1 (en) | 2015-04-20 | 2016-10-27 | Etubics Corporation | Methods and compositions for combination immunotherapy |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3399943B2 (ja) * | 1991-05-06 | 2003-04-28 | アメリカ合衆国 | 癌胎児性抗原を発現する組換えウイルスとその使用方法 |
US6001349A (en) * | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
-
1998
- 1998-09-22 AT AT04011673T patent/ATE364048T1/de active
- 1998-09-22 EP EP98948429A patent/EP1017810B1/de not_active Expired - Lifetime
- 1998-09-22 DE DE69837896T patent/DE69837896T2/de not_active Expired - Fee Related
- 1998-09-22 PT PT04011673T patent/PT1447414E/pt unknown
- 1998-09-22 WO PCT/US1998/019794 patent/WO1999019478A1/en active IP Right Grant
- 1998-09-22 JP JP2000516030A patent/JP4291508B2/ja not_active Expired - Lifetime
- 1998-09-22 ES ES98948429T patent/ES2217585T3/es not_active Expired - Lifetime
- 1998-09-22 AT AT98948429T patent/ATE267213T1/de not_active IP Right Cessation
- 1998-09-22 DE DE69824023T patent/DE69824023T2/de not_active Expired - Lifetime
- 1998-09-22 CA CA2308127A patent/CA2308127C/en not_active Expired - Lifetime
- 1998-09-22 ES ES04011673T patent/ES2286530T3/es not_active Expired - Lifetime
- 1998-09-22 DK DK04011673T patent/DK1447414T3/da active
- 1998-09-22 AU AU95004/98A patent/AU745863B2/en not_active Expired
-
2007
- 2007-07-30 CY CY20071101013T patent/CY1107706T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE69824023T2 (de) | 2005-05-12 |
CA2308127C (en) | 2011-03-22 |
AU745863B2 (en) | 2002-04-11 |
JP2002500002A (ja) | 2002-01-08 |
ATE364048T1 (de) | 2007-06-15 |
WO1999019478A1 (en) | 1999-04-22 |
ES2286530T3 (es) | 2007-12-01 |
EP1017810A1 (de) | 2000-07-12 |
DK1447414T3 (da) | 2007-09-10 |
ES2217585T3 (es) | 2004-11-01 |
CY1107706T1 (el) | 2013-04-18 |
EP1017810B1 (de) | 2004-05-19 |
JP4291508B2 (ja) | 2009-07-08 |
DE69837896D1 (de) | 2007-07-19 |
PT1447414E (pt) | 2007-07-18 |
AU9500498A (en) | 1999-05-03 |
DE69837896T2 (de) | 2008-02-14 |
DE69824023D1 (de) | 2004-06-24 |
CA2308127A1 (en) | 1999-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107706T1 (el) | Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea) | |
ATE272070T1 (de) | Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen | |
MY109957A (en) | Improved antibodies to plasmodium falciparum | |
DK0606317T3 (da) | Saponin-antigen-konjugater og anvendelsen deraf | |
DK0529023T3 (da) | Terapeutisk anvendelige peptider og peptidfragmenter | |
ATE163195T1 (de) | Lösliche liganden für cd40 | |
GEP20074091B (en) | Cripto blocking antibodies and uses thereof | |
NZ605429A (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
SG96535A1 (en) | Pharmaceutical composition for the treatment or prevention of a malignant tumor | |
GR3026219T3 (en) | Mouse monoclonal antibodies | |
EP1064308A4 (de) | Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen | |
EP0739350A4 (de) | Fas-antigenbindender ligand | |
DE69736306D1 (de) | Rezeptor von dendritischen zellen. | |
BR9709958A (pt) | Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso | |
WO2001079259A8 (en) | Javelinization of protein antigens to heat shock proteins | |
ES2177927T3 (es) | Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico. | |
ES2179187T3 (es) | Oriteuba qye se yba a cd40 para estimular una respuesta inmune. | |
EP0972054A4 (de) | Steigerung der immunantwort unter verwendung von zielgerichteten molekülen | |
EP1447414A3 (de) | Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität | |
PT723552E (pt) | Oligopeptidos derivados de fragmentos de proteina reactiva c | |
DE3855280T2 (de) | Von mca 16-88 erkanntes antigen | |
IL84040A (en) | Monoclonal antibodies against ifn-omega,their preparation and their use in the purification and detection of ifn-omega | |
DE69637435D1 (de) | Saponin-zusammensetzungen und deren verwendung | |
ATE480250T1 (de) | Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion | |
ES2199047A1 (es) | Metodo de diagnostico inmunologico de la dirofilariosis pulmonar humana |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |